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ABSTRACT
The pharmacological potential of bioactive compounds extracted from mushrooms has been studied to a reasonable level. In the same vein, the 
bioactivity of nanoparticles has also been investigated and reported to be of potential pharmacological benefit. No doubt, there is a reasonable 
amount of claims regarding the vast activity of the mushroom extracts and nanoparticles on the tested cell lines and microorganisms. In this paper, 
a review of the recent application of bioactive compounds extracted from two edible mushrooms (Coprinus comatus and Lactarius deliciosus), as 
well as some of the recently reported studies on some nanoparticles of pharmacological potentials, was carried out. In order to check for synergy in 
the bioactivity of the mushroom extracts when co-administered with nanoparticles, an investigation on the synergistic application of the materials 
through the encapsulation of the bioactive extracts from the mushroom onto the nanoparticle was proposed. The supposed synergy in the activity of 
the extract-nanoparticle complex could hold the key to improved activity of nutraceuticals against resistant microorganisms and tumor cells.
Keywords: Coprinus comatus, Lactarius deliciosus, Nanoparticles, Synergy, Bioactive extracts.
INTRODUCTION
In the days and even presently, mushrooms are consumed all over the 
world by people for their nutritional and culinary potentials. Due to the 
high protein, low fat, and cholesterol contents of mushrooms, they are 
considered by many people to be a vital component of daily meals as 
a source of nutritional ingredients such as minerals, polysaccharides, 
flavonoids, and polyphenols [1]. Some polyphenolic compounds derived 
from mushrooms have been found to possess powerful antioxidant 
activities, with free radical scavenging and metal chelating activities [2]. 
Recent researches provide consistent approval for the development of 
ethnomedicine [3]. More evidence has been provided using bioactive 
materials extracted from mushrooms [4], as well as polysaccharides 
isolated from Ganoderma lucidum and Trametes versicolor [5], which 
showed great expression of tumor markers [4], increased natural killer 
cells activities, and higher survival rate [5]. Following the successful 
trials, polysaccharides isolated from T. versicolor had further been 
approved in Japan and marketed as an antitumor drug known as 
Krestin (PSK). Further utilization of the pharmacological potentials of 
natural materials could be the key to solving the emerging challenges of 
new diseases and drug-resistant variants.
The current emergence of the superbug, increased cancer epidemics 
and multidrug-resistant bacteria strains is pushing for an urgent need in 
the provision of antibacterial compounds that could be novel enough to 
combat the threat of these organisms. As a result of mushrooms’ natural 
living environment (life cycles which depend on degrading dead organic 
matters) and the need to defend against pathogenic organisms in their 
environment, it is believed that potent antimicrobial and cytotoxic 
compounds could be extracted from mushrooms [6]. This prospect 
is supported by a previously reported case, whereby antimicrobial 
farnesyl hydroquinones (ganomycin A and B) isolated from Ganoderma 
pfeifferi were found to inhibit the growth of methicillin-resistant 
Staphylococcus aureus [7].
With this supporting evidence, it is certain that work has previously been 
done on the cytotoxicity of bioactive substances extracted from Coprinus 
comatus and Lactarius deliciosus. However, it could be interesting to 
extend the present knowledge on the pharmacological properties of 
these bioactive compounds from C. comatus and L. deliciosus by studying 
the cyto-effects when coupled on a nanoparticle with pharmacological 
potentials. Some nanomaterials have been synthesized in a nanoscale 
(<100 µm) and a handful of these materials tested against notable human 
cell line for cytotoxic and antibacterial activities. Among the nanomaterials 
synthesized and tested were sulfated zirconia nanoparticles, cerium, 
single-walled carbon nanotubes (SWCNTs) to mention but a few [8]. 
Although nanoparticles are most suitable for delivering of hydrophobic 
drugs, several reports have shown success in encapsulating hydrophilic 
drugs through surface attachment or polymer drug conjugation 
methods [9]. Many approaches have also been taken to co-encapsulate 
multiple therapeutic agents into a single polymeric nanoparticle. Drugs 
can be attached to the nanoparticles using either of the following ways:
a. Direct encapsulation of drugs into the hydrophobic polymeric core 
of the nanoparticle
b. Incorporation of an additional medium to the nanoparticle, usually 
on the particle surface to create a separate partition for drug loading
c. Covalent conjugation of drugs to the polymer backbone during the 
synthesis of the nanoparticle.
Hence, in this article, a mini review of the current studies on two 
edible mushrooms (C. comatus and L. deliciosus) as well as a review 
of selected nanoparticles of pharmacological interest was conducted. 
The recent applications of the bioactive compounds extracted from the 
selected mushrooms, as well as the application of nanoparticles for 
pharmacological benefits, were carried out. At the end of the review, 
a proposal for the synergistic utilization of the bioactive compounds 
extracted from the mushrooms, together with the nanoparticles for 
an improved antibacterial and antitumor activity against selected 
microorganisms and tumor cells, was made.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i3.15406
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MUSHROOMS
Mushrooms, also known as toadstools, are group(s) of the fleshy, spore-
producing, and fruiting body of fungi, commonly springing from the 
ground or on the food source where they grow as saprophytes. Generally, 
mushrooms are commonly identified through the application of the 
basic understanding of their macroscopic features. Most mushrooms 
are classified as Basidiomycetes, with characteristic possession of 
much-developed gills, which are arranged in a room-like pattern. 
Mushrooms possess spores (basidiospores) which are produced on the 
gills and when matured fall off in a fine rain manner from the underside 
of the caps, facilitating its dispersals [10]. Typically, mushrooms are the 
fruit bodies of the order Agaricales, but with the evolution of molecular 
classification, not all the members of this order can produce the typical 
fruit bodies but possess gills, placing them in the class Agaricomycetes. 
For instance, the milk cap mushrooms (Lactarius and Lactifluus) and 
russulas (Russula), as well as Lentinellus, belong to the Russulales [2].
Mushrooms can be grouped as edible or poisonous, suggesting that 
mushroom may be eaten, toxic, or unpalatable with the human body. The 
edible mushrooms are cultivated in controlled (or wild) environment for 
human consumption owing to their low caloric content and abundance 
of bioactive compounds which are beneficial to human health. The 
poisonous (toxic) mushrooms are known to contain substances which 
are toxic to the human body when eaten. Most of the toxins are believed 
to possess neurotoxic, nephrotoxic, hepatotoxic, as well as psychotic 
effects [11]. Medicinally, mushrooms possess bioactive compounds 
which have been studied and documented as potential sources of 
nutraceuticals owing to their potency against reactive oxygen species 
(ROS) and tumor cell inhibition. Mushrooms also possess antimicrobial 
activities which have been effective against the Gram-positive and the 
Gram-negative bacteria [2,12]. The ability of mushroom farmers to 
cultivate some of the medicinal mushrooms in commercial quantity 
has boosted the recent advances toward the utilization of the bioactive 
compounds from mushrooms for pharmacological and therapeutic 
purposes. Within the scope of this research, a critical review will be 
focused on two identified medicinal mushrooms (L. deliciosus and 
C. comatus). The review will focus on the geographical location (habitat), 
the nutritional benefits, the pharmacological importance of the bioactive 
compounds, and the economic importance of the discussed mushrooms.
Clinical evidence of mushroom extracts as pharmacological agents
Various mushroom polysaccharides have gone into clinical trials in 
cancer patients, most of which, however, have just been studied in non-
randomized trials with a small number of patients. These trials have 
been carried out exclusively in the Far East although some have already 
begun in the United States. Safety during clinical assessments has been 
good, with no maximum tolerated dose for these compounds currently 
reached, and making the potential of a prolonged use of these compounds 
without side effects a possibility. Griffon-D, a mushroom-based product, 
has recently been excluded from Phase I study by the FDA because of 
the lack of preclinical toxicity. Even though some of these mushroom 
compounds have not been tried in the Western standard randomized 
trials, there are strong proof-of-principle data for some medicinal 
mushrooms to support further studies [13]. Trials with compounds 
isolated from Agaricus bisporus [14,15] and some species of Pleurotus 
[16] have shown both in vitro and in vivo anti-inflammatory activities, 
whereas extracts from L. deliciosus have also been put to clinical trials.
Methanol extracts of L. deliciosus have been tested to assess the potential 
anti-inflammatory activity of the mushroom using macrophages 
RAW 264.7 by Moro et al., who reported that the extracts were able 
to affect the viability of the cells, except at a lower concentration 
of 0.5 mg/mL [14]. This report was supported by a bar chart presenting 
a comparative study of six mushrooms (A. bisporus, Boletus edulis, 
Cantharellus cibarius, Craterellus cornucopioides, L. deliciosus, and 
Pleurotus ostreatus) with the conventional anti-inflammatory agent, 
lipopolysaccharide (LPS). The data showed that L. deliciosus portrayed 
the highest anti-inflammatory activity against the macrophages and 
stood to argue that the high total phenolic content of the L. deliciosus could 
be a reason for its strong anti-inflammatory activity [14]. The ability of 
the bioactive extracts of L. deliciosus has also been tested for its ability 
to stimulate the production of nitric oxide (NO) (a substance produced 
by macrophages when stimulated). The macrophages were incubated 
with the extracts for 1 hr and later stimulated with LPS (1 µg/mL) for 
24 hrs, and the level of NO release was measured by the accumulation 
of the metabolite nitrite in the culture supernatant. The macrophages 
that were not stimulated were found to produce no NO, while those 
stimulated with the LPS presented a high level of NO production [14]. 
The results showed that extracts from some of the mushrooms studied 
inhibited LPS-induced NO production and the expression of pro-
inflammatory cytokines, such as interleukin-1b (IL-1b) and IL-6. The 
overproduction of these mediators has been implicated in various 
inflammatory diseases and cancer [17]. The inhibition of the activation 
of these mediators seems to be an important target for the treatment 
of inflammatory diseases. The most efficient species among the studied 
species were C. cibarius, L. deliciosus, and A. bisporus while others such 
as B. edulis and P. ostreatus had no effect [18].
Although many natural substances may take part in anti-inflammatory 
activities, phenolic compounds have been recognized as natural 
molecules with most potent anti-inflammatory effects. Positive 
correlations have been established between total phenolic content 
and anti-inflammatory effects of different mushroom extracts [19,20]. 
Phenolic compounds consist of a range of substances which display a 
great diversity of structures and their biological activity may be highly 
influenced by the chemical nature of the components. Even though 
phenolic acids are the most abundant compounds in most mushroom 
species, their content may not correlate with the inhibitory potential 
of the extracts and stands to reason that the contribution of these 
compounds to the anti-inflammatory activity is not relevant.
To justify this, studies carried out to establish the effect of derivatives 
on the production of inflammatory agents concluded that derivatives, 
such as caffeic acid, ferulic acid, chlorogenic acid, and p-hydroxybenzoic 
acid, from an ethanolic plant extract, did not affect the production 
inflammatory agents [21]. Furthermore, pyrogallol, which is present in 
extracts of A. bisporus, C. cibarius, C. cornucopioides, and L. deliciosus [14], 
may be responsible for the anti-inflammatory activity observed in the 
extracts of these mushrooms since these extracts were the most active in 
terms of NO inhibition. Synergisms between pyrogallol and other active 
compounds present in the extracts from L. deliciosus, and other studied 
mushrooms such as flavonoids or cinnamic acid derivatives could partly 
explain the differences in activity of the studied extracts [14].
L. DELICIOSUS
L. deliciosus, best known as the saffron milk cap or red pine mushroom, 
belongs to the genus Lactarius and order Russulales. It is among the 
best-known members of the large milk cap mushrooms found mainly 
in Europe and but accidentally has been introduced to other countries. 
It can be found growing in pine plantations and related environments 
where the environment is favorable [22]. L. deliciosus possesses a carrot 
orange cap, which is convex to vase-shaped. When young, it is in-rolled, 
measuring about 4-14 cm (1.5-5.5 inch) in diameter, usually with 
darker orange lines arranged in concentric circles. The cap is viscous 
and sticky when wet although it is often dry. The gills are crowded and 
decurrent with a squat hollow orange stipe often measuring 3-8 cm 
(1-3 inch) in length and about 1-2 cm (0.5-1 inch) in thickness. When 
handled, L. deliciosus stains with a deep green color; however, when 
fresh, the mushroom produces orange-red “milk” which does not 
change color [22]. Mycologically, L. deliciosus possesses gills on the 
hymenium and has a depressed cap, hymenium is decurrent, stipe is 
bare, spore print is tan, and ecology is mycorrhizal, while edibility is 
purely on choice.
Nutritional benefits of L. deliciosus
The major compounds found in mushrooms are carbohydrates and 
proteins. Total protein content varying between 21% and 50% has 
been reported, which competed with protein from meat, milk, and egg. 
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Mushrooms are also consumed due to their low-calorie content 
(1.40-10.58%) [23]. Analysis of the chemical composition of L. deliciosus 
showed that it contained 8.75%, 2.64%, 75.25%, and 4.61% of moisture, 
fat, protein, and ash, respectively, representing approximately 89.96% 
of the total dry material [24]. Although similarities in the composition 
of mushrooms exist, the chemical composition of mushrooms is 
usually affected by a number of factors, which includes mushroom 
strains, growth media composition, environment, harvesting time, 
handling conditions, and substrates preparation. There is diversity in 
the antimicrobial and antitumor activity of mushrooms at different 
stages of cultivation of the same species due to changes in the content 
and amount of active compounds according to the growth media and 
environment of the mushroom [25].
Wild edible mushrooms such as L. deliciosus are popular food stuff 
with reported high levels of proteins, zinc, vitamins, iron, sodium, 
and minerals, which could be a major component of the mushroom 
or could be absorbed from the surrounding environment. This could 
be the reason for a higher composition of minerals and chemicals in 
wild mushrooms [26]. Because mushrooms aid in the breakdown 
of organic matter and play a role in the natural decomposition of 
materials, a very effective mechanism for the accumulation of heavy 
metals from the environment persists in mushrooms, especially the 
wild mushrooms [27]. These metals are part of the nutritional benefits 
from mushrooms since most of the metals act as cofactors for most of 
the complex enzyme systems.
Pharmacological potentials of L. deliciosus
Pharmacologically, the application of mushroom extracts in medicine has 
been researched and various reports have been documented regarding 
the health benefits of extracts from the mushroom. In pharmacological 
trials, bioactive compounds from L. deliciosus have been tested against a 
wide range of bacteria and tumor cells owing to their radical scavenging 
properties and phenolic content [12,28]. Jayakumar et al. reported that 
wild mushrooms can be used for therapeutic purposes because they 
produce varieties of metabolites, such as organic acids, terpenoids, 
alkaloids, and phenolic and steroid compounds [29]. Health beneficial 
properties, such as antioxidant, antimicrobial, anticancer, cholesterol-
lowering activities, and immune stimulatory effects, have all been 
reported for species of mushrooms including L. deliciosus [12,28].
The radical scavenging properties and the total phenolic content of 
L. deliciosus have been studied by various researchers and compared 
with other wild and cultivated mushrooms. The results of the previous 
studies on L. deliciosus compared with other mushrooms are presented 
in Table 1.
The rate of antioxidant activity depends on the mushroom species and 
also on the solvent used for extraction. Various reports suggested that 
the radical scavenging activities of most extracts depend on the total 
phenolic content as extracts with higher total phenolic were seen to 
possess high radical scavenging properties [12,32,33].
L. deliciosus is an important source of natural antioxidants such as 
phenolic compounds (tocopherols, flavonoids, and phenolic acids), 
nitrogen compounds (alkaloids, amino acids chlorophyll derivatives, 
and amines), or carotenoids as well as ascorbic acid. These are 
molecules produced as secondary metabolites with great therapeutics 
effects. The consumption natural foods such as mushroom provide 
supplements and antioxidants which help to protect the body against 
various diseases, such as cancer, heart, and cerebrovascular diseases. 
They may also help the human body in reducing oxidative damage or 
protect oxidative deterioration, usually develop as a result of stress. Both 
the fruiting body and the mycelium of L. deliciosus contain compounds 
which exhibit both antioxidant and antimicrobial activities. Specific 
compounds are extracted to produce antibiotic or pharmaceutical 
drugs for combating various forms of diseases [25,31].
Due to the high polyphenol content of L. deliciosus, it has been 
reported by Elmastas et al. to be superior in anthocyanin content 
(1.38±0.09 mg cyaniding 3-glucoside/g dry weight) among 12 screened 
mushroom species and this conferred a great pharmacological 
activity on L. deliciosus [31]. The radical scavenging property of 
L. deliciosus has also been reported to be higher than the activity of 
most conventional antioxidants such as butylated hydroxytoluene and 
trolox [12]. Early research has shown that isolates from mushrooms 
have anticancer, cardiovascular, antiviral, antiparasitic, antibacterial, 
anti-inflammatory, blood lipid-lowering, immune response stimulating, 
and even antidiabetic effects [34-36]. Currently, extracts from several 
mushrooms including L. deliciosus have widespread application in 
Japan, Korea, and China, being used as potential adjuvants to radiation 
and chemotherapy [10,13].
Antibacterial potential of L. deliciosus extracts
The bioactive compounds (phenolic and flavonoids) of L. deliciosus 
have been extracted using different extracting medium and tested for 
activities against selected microorganisms for potential use as natural 
antimicrobial agents. Baros et al. studied the antimicrobial properties 
of phenolic extracts of Portuguese wild edible mushroom species 
(L. deliciosus, Sarcodon imbricatus, and Tricholoma portentosum) 
against microbial pathogens. In the report, it was demonstrated that 
L. deliciosus had the greater effect on all the tested microorganisms 
owing to its higher total phenolic content. The observed total phenolic, 
flavonoids and ascorbic acid contents of L. deliciosus extracts were 
17.25±0.65, 8.14±0.81, and 0.24±0.02 mg/g, respectively [12]. When 
the extracts were tested against Bacillus cereus, Bacillus subtilis, 
Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and 
Cryptococcus neoformans, L. deliciosus extracts expressed a strong 
antibacterial inhibitory activity against all the species tested at a 
minimum inhibitory concentration (MIC) of 10 mg/mL, except for 
E. coli, where even a higher of 300 mg/mL showed no inhibitory 
activity. E. coli expressed strong resistance to all the tested extracts 
from the three mushrooms tested, implying that the resistance to the 
extracts of L. deliciosus was not in isolation, but a general phenomenon 
likely due to gene variation [12].
Dilsad et al. studied the antimicrobial, antioxidant activities and 
chemical composition of L. deliciosus collected from Kastamonu 
Province of Turkey and reported that the highest inhibitory activity was 
found against P. aeruginosa with an inhibition zone of 30±00 mm using 
acetone and ethanol as extraction solvents. The study equally reported 
weak inhibitory action against S. aureus and C. albicans with a zone of 
inhibition measuring <9 mm in diameter using dimethylsulfoxide and 
distilled water as extraction solvents [23]. The antibacterial activity 
of most bioactive compounds depends on the solvent used during 
extraction. Various reports of varying activities have been reported 
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regarding the antibacterial activities of L. deliciosus extracts, which 
seem to be higher when extracted with methanol, as compared to other 
extraction solvents. Dulger et al. reported that methanol extracts of 
L. delicious have been found to be effective against Mycobacterium sp. 
and greater antimicrobial activity against Gram-positive and 
Gram-negative bacteria, with little or no effect against yeasts [37].
Among the Lactarius spp., various studies have shown a different 
pattern of antimicrobial sensitivity among the members of the 
group, especially against E. coli. Looking at the individual reports 
among the Lactarius spp., Ozen et al. reported that among Lactarius 
piperatus, Lactarius camphorates, Lactarius volemus, and L. delicious, 
L. camphorates showed more antibacterial activity against E. coli and 
other studied organisms [25], whereas Dulger et al. reported that 
L. deliciosus was more effective against E. coli than other members 
of the Lactarius family [37]. Barros et al. studied the effect of fruiting 
body maturity stage on the chemical composition and antimicrobial 
activity of Lactarius spp. mushrooms and reported that L. deliciosus 
had the highest antibacterial effect against E. coli among the six species 
studied [1].
Antitumor potential of L. deliciosus extracts
Based on available literature, a few reports have been documented 
on the antitumor activities of whole extracts from L. deliciosus. 
However, there have been reports on the antioxidant and scavenging 
potentials of extracts from L. deliciosus. Having known the role of the 
total phenols and flavonoids in radical scavenging, more works on the 
antitumor potential of the extract from L. deliciosus becomes inevitable. 
Marijana et al. studied growth inhibitory effects of methanol extracts 
of L. deliciosus on human epithelial carcinoma (HeLa), human lung 
carcinoma (A549), and human colon carcinoma (LS174) cell lines and 
reported that the mushroom showed anticancer potential with an 
IC50 against tested cells ranging from 19.01 mg/mL to 80.27 mg/mL. 
The IC50 for L. deliciosus against HeLa, A549, and LS174 cells lines was 
19.01, 33.05, and 74.01 mg/mL, respectively [27]. This is the only 
reported investigation into the anticancer potential of L. deliciosus crude 
extract against cell lines, thereby paving the way for the investigation of 
the antitumor activities against a broader range of cell lines.
Some works have also been reported on the activity of some 
polysaccharides extracted from this mushroom, having antitumor 
activities. Ding et al. reported a novel polysaccharide from L. deliciosus 
during the study of the structure, feature, and antitumor activity of a 
novel polysaccharide isolated from L. deliciosus gray. The polysaccharide 
codenamed LDG-A was used on mice S180 tumor to evaluate the 
antitumor effects of the polysaccharide [38]. From the results, LDG-A 
was found to be able to inhibit the growth of the tumors in a dose-
dependent fashion. The rate of inhibition in the mice treated with 
about 80 mg/kg LDG-A was found to be 68.422%, which actually was 
the highest dose tested, thereby showing the greatest rate of inhibition. 
The antitumor activity of the isolated polysaccharide was believed to 
be a result of the activation of the cell-mediated immune response in 
the host [39]. A summary of the antitumor activity of the L. deliciosus 
polysaccharide isolated by Ding et al. is shown in Table 2.
From the results, Ding et al. observed that there was minimal change 
in the average liver weight of the test groups, which indicated that the 
LDG-A from L. deliciosus did not cause serious liver damage and could 
be a potential antitumor agent with a good chemotherapeutic index. 
The study concluded that the activation of the immune responses in 
the host might likely be one of the mechanisms of antitumor activity 
of LDG-A, which has been the case for many antitumor polysaccharides 
already in use.
Antioxidant potential of L. deliciosus extracts
The antioxidant potential of L. deliciosus has been investigated and 
reported by a number of authors. The most common method of 
investigating the antioxidant potential of the mushroom has been 
the scavenging of 1,1-diphenyl-2-picryl-hydrazil (DPPH). Marijana 
et al. reported that methanol extracts of L. deliciosus showed lower 
scavenging property when compared to the standard ascorbic acid 
which served as the control. The extracts of L. deliciosus had a DPPH 
radical scavenging (IC50) of 493.82±2.35 µg/mL, which was much lower 
than the 6.42±0.18 µg/mL of the ascorbic acid which served as the 
control [27]. Similarly, Ferreira et al. studied the free radical scavenging 
capacity and reducing power of wild edible mushrooms from Northeast 
Portugal and reported that the extracts of L. deliciosus had higher 
scavenging property on DPPH when compared to the scavenging power 
of T. portentosum. The L. deliciosus extract presented a scavenging ability 
of 79.1-84.3% at 50 mg/mL which was better than the 30.4-65.0% 
at 50 mg/mL of T. portentosum. Butylated hydroxyanisole (BHA) and 
α-tocopherols were used as controls, presenting higher scavenging 
effects of 3.6 mg/mL for BHA and 8.6 mg/mL for α-tocopherols being 
96% and 95%, respectively. They also reported that the extracts 
obtained from the cap of the mushroom scavenged DPPH radicals 
at a higher percentage that extracts from the other parts (body and 
rhizomes) of the mushroom [30].
Studying the antioxidant, antimicrobial activities and chemical 
composition of edible mushrooms grown wildly in the Black Sea Region 
of Turkey, Ozen et al. reported that all the tested mushrooms, including 
the extracts from L. deliciosus, showed moderate scavenging effects on 
DPPH. The level of scavenging effects was lower in some mushrooms 
studied compared to α-tocopherols including L. deliciosus (51%) 
than the scavenging effects of α-tocopherols (60%) which served as 
control. The scavenging effects of extracts from Ramaria flava (80%), 
Macrolepiota procera (69%), L. volemus (61 %), Lactarius camphoratus 
(61 %), and L. piperatus (61 %) were higher than the scavenging effects 
of α-tocopherols (60%) [25].
C. COMATUS
C. comatus or lawyer’s wig is a macrofungus often seen growing along 
gravel roads and lawns. Sometimes, they are seen growing on dirty 
areas with the young fruiting bodies appearing first as white cylinders 
growing up from the ground, followed by the bell-shaped caps which 
open out later. When the caps opened, the gills under the cap are white, 
then changes to pink, and finally turns black before secreting a black 
liquid that is filled with the spores. This is the reason it is sometimes 
regarded as the “ink cap.” Due to the short lifespan of this mushroom, it 
is unusual because as soon as it turns black, it auto dissolves in a matter 
of hours. Long-term storage of the mushroom can be achieved through 
drying, freezing, or microwaving [40]. Taxonomically, C. comatus is a 
species belonging to the genus Coprinus.
This genus Coprinus was originally considered as a large genus with 
over 100 species. However, on molecular analysis of DNA sequences, 
it showed that the former species belonged to two families, known 
as the Agaricaceae and the Psathyrellaceae. The species C. comatus is 
the best known of the member of the true Coprinus [41]. Descriptively, 
C. comatus is easily recognized by its cylindrical mostly whitish shaggy 
cap that initially covers most of the stem. The cap of the mushroom is 
usually paler and uses to change from white to pink rapidly before finally 
turning black. It absorbs water from the environment when exposed, 
conferring to it the deliquescent status. It has stipe which usually 
measures about 10-37 cm in height and about 1-2.5 cm in diameter. 
At the microscopic level, it does not possess pleurocystidia, and the 
spore print is usually blackish brown, with the spores measuring about 
10-13 µm. It has a whitish flesh and also tastes mild [41].
Nutritional benefits of C. comatus
C. comatus when young contains about 25% proteins and is also rich 
in triglycerides, mainly made up of linoleic acid. Traditionally, it is 
used in Chinese medicine for the treatment of piles and to improve 
digestion [42]. The consumption of C. comatus has been reported 
to cause recovery from alcoholic effects when tried in experimental 
animals [43]. The total energy derivable from 100 g of the mushroom is 
about 349 Kcal, meaning it is usually low in caloric content. The protein 
content is about 37 %, water content made up about 13.5%, ash content 
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accounted for about 5.5%, while fats and oil and carbohydrates contents 
accounted for 5% and 39%, respectively [43]. A profile of the fatty acid 
content of the extracts from C. comatus using GC-FID showed that it is 
majorly composed of linoleic acid (C18:2n6c) (66.6%), palmitic acid 
(C16:0) (11.8%), palmitoleic acid (C16:1) (5.4%), stearic acid (C18:0) 
(3.3%), oleic acid (C18:1n9c) (6.1%), and linolenic acid (C18:3n3) 
(1.1%). These are lipids that have been proven to be of beneficial use 
to the normal functioning of the brain and the nervous systems [44]. 
The vitamin content of C. comatus was also investigated and reported to 
contain the following vitamins at the following concentrations: Thiamin 
(vitamin B1) (7.5 mg/100 g), riboflavin (vitamin B2) (0.45 mg/100 g), 
retinol (vitamin A) (<50 mg/100 g), ascorbic acid (vitamin C) 
(6.15 mg/100 g), α-tocopherols (vitamin E) (<1 mg/100 g), and 
niacin+niacinamide (vitamin B3) (<1 mg/100 g) [44]. These indicated 
that the mushroom is a good source of the important vitamins required 
for daily body function.
Antibacterial potentials of C. comatus extracts
The antibacterial activity of methanolic extracts both cultivated and 
wild C. comatus has been previously investigated by Dejan et al. and 
documented as follows: The samples from both cultivated and wild 
C. comatus showed strong antibacterial activity against all the bacteria 
that were tested. Wild and cultivated extracts of C. comatus exhibited 
the highest antibacterial activity against S. aureus (MIC of 0.0625 and 
1.5 mg/mL; minimum bactericidal concentration [MBC] of 0.125 and 
3.0 mg/mL) and B. cereus (MIC of 0.0625 and 0.75 mg/mL; MBC of 
0.125 and 3.0 mg/mL). The lowest observed antibacterial activity 
was achieved recorded against E. coli with MIC of 3.0 mg/mL and 
MBC of 6.0 mg/mL. The methanolic extract of the cultivated C. comatus 
extract was reported with higher antibacterial potential in general, as 
compared to the extracts from the wild sample. This could be attributed 
to the controlled environment, in which the cultivated mushroom was 
grown. It was also reported that against E. coli, both extracts exhibited 
the same level of activities [45]. A summary of the activities of the wild 
and cultivated extracts of C. comatus as was documented by Mull et al. 
is presented in Table 3.
Similarly, Ehssan et al. studied antibacterial activity of wild mushrooms 
from the Khartoum state of Sudan and reported that the ethanol extract 
of C. comatus was very active against almost all of the tested organisms, 
except for Aspergillus niger where it showed some resistance. It was 
also reported that the petroleum extracts from the mushroom were 
not active against all the tested organisms [46]. These activities were 
concluded to be due to the presence of bioactive compounds such 
as alkaloids, flavonoids, phenolic, saponins, sterols, carbohydrates, 
tannins, coumarins, and cyanogenic glycosides, as well as the solubility 
of these compounds in the extraction solvent.
Kalaw and Albinto studied the functional activities of Philippine wild 
strain of C. comatus and Pleurotus cystidiosus grown on rice straw and 
noted that ethanol and acetone extracts of the mushrooms were able to 
inhibit the growth of S. aureus though C. comatus ethanol extract showed 
a wider zone of inhibition, recording a mean inhibition diameter of 
14.09 mm, as compared to acetone extract, with a mean inhibition 
diameter of 13.43 mm. However, on the other hand, it was reported 
that P. cystidiosus acetone extract showed a larger inhibition zone with 
a mean diameter of 15.25 mm than that of ethanol extract which has a 
mean diameter of 13.16 mm. No activity was recorded against E. coli 
when the ethanol and acetone extracts of both mushroom species 
were tested against the bacteria. This showed that both mushrooms 
can exhibit potential antibacterial activities, but the extent of activity 
depends on the solvent used during the extraction process [47]. 
Furthermore, Srivastava and Sharma showed that the antimicrobial 
activity of mushroom depends on the solvent used for extraction as 
well as the strain of the fungus. Similarly, Iwalokun et al. demonstrated 
that petroleum ether and acetone extracts of P. ostreatus inhibited the 
growth of both Gram-positive and Gram-negative bacteria, as well as 
fungi, tested [35,48].
Antitumor potential of C. comatus extracts
Studies on the antitumor potential of extracts from C. comatus against 
selected cell lines have been investigated and reported previously, with 
recommendations for further studies on other range of human cancer 
cell lines. Few of the works already reported showed that the mushroom 
has antitumor potential against tested cell lines due to the abundance 
of phenolic and flavonoids in the mushroom. Zaidman et al. studied 
the effects of C. comatus and G. lucidum interference with androgen 
receptor function in LNCaP prostate cancer cells and reported that the 
extracts of both mushrooms inhibited the proliferation of the prostate 
cancer LNCaP cells with IC50 values of 28.3 g/mL for C. comatus and 
44.8 l g/mL for G. lucidum. However, interestingly, they also reported 
that a significantly higher concentration of the C. comatus extract 
was needed to cause 50 % growth inhibition of the other tested cell 
lines, meaning that the C. comatus extract had an appreciable level 
of selectivity toward LNCaP cell lines, as compared to the extracts of 
G. lucidum which showed lesser selectivity [42]. The study also showed 
that the extracts of C. comatus were able to selectively affect the cell 
cycle progression of prostate cancer PCa cell lines, comprised LNCaP, 
PC-3, and DU 145.
Small and Roach studied the effects of C. comatus and G. lucidum extracts 
on the level of secreted prostate-specific antigen (PSA) from LNCaP cell 
line in a dose-dependent manner study and found that the extracts 
successfully decreased the level of PSA secreted while treatment with 
dihydrotestosterone (DHT) caused an increase in the level of secreted 
PSA by 2.47-fold [49]. Zaidman et al. in a similar manner also studied 
the effect of DHT treatment of LNCaP cells (PSA release) and compared 
it with the treatment of C. comatus extract. The results showed that the 
treatment with DHT caused an appreciable increase in the level of PSA 
whereas treatment with flutamide caused a moderate reduction in the 
PSA production level. However, with the C. comatus extract treatment, 
a significant decrease in the level of PSA levels in a dose-dependent 
manner [42].
In another study, Rouhana-Toubi et al. studied the effect of dry powder 
of C. comatus fruiting bodies extracted using ethyl acetate on the 
viability of three cell lines from human ovarian cancer (ES-2, SKOV-3, 
and SW-626). In the conclusion of the study, they reported that the 
mushroom extract was very active against all the tested cell lines, in 
a dose-dependent manner. However, to know which fraction of the 
crude extract was more active against the cells, the crude extract was 
subjected to purification using chromatography on a silica gel column. 
At the end of the purification and further testing of the resulting six 
different fractions on the cells, they observed more significantly 
effective action with the last elute than the crude extract in the 
reduction of cell viability. To cap it all, the study summarized that the 
Table 2: Anti-tumor activities of L. deliciosus (LDG-A) polysaccharide on S180 tumor
Group Spleen index (mg/g) Liver index (mg/g) Thymus index (mg/g) Average tumor weight (g) Inhibitory rate of 
tumor (%)
Negative control 5.784±2.108 60.307±9.395 1.429±0.706 3.740±0.423 -
20 mg/kg 7.619±2.414 56.468±4.509 4.741±0.301 2.081±0.740 44.358
40 mg/kg 7.807±3.427 66.351±8.802 7.790±3.208 1.783±0.430 52.326
80 mg/kg 5.202±0.989 59.977±4.786 0.903±0.401 1.181±0.241 64.422
Positive control 7.0439±3.105 58.263±5.399 2.862±1.727 1.581±0.706 57.727
Adapted from [38]
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ethyl acetate extract of C. comatus reduced the viability of the three 
cell lines of human ovarian cancer [50]. These reports from previous 
studies suggest that the tendency of producing antitumor drugs from 
natural sources, especially from mushrooms, is realizable.
Further studies on the ways to promote the delivery of the drugs to 
the target cells and the possibility of a synergy in the action of the 
compounds with other compounds or materials of pharmacological 
interests deserve investigation for enhanced activities. The 
potential of nanoparticles serving as therapeutic and delivery 
agents has been investigated, and various reports suggested that 
nanoparticles can be applied directly as a therapeutic agent against 
human cancer proliferation as well as a dependable delivery agent 
of bioactive compounds [8,51]. On this note, a mini review of 
some of the nanoparticles of pharmacological importance is been 
carried out, with a view of finding out the particular properties and 
characteristics that confer the status of a pharmacological important 
particle. Furthermore, a review of the possible ways to encapsulate 
the bioactive compounds extracted from the studied mushrooms on 
the nanoparticle of interest for better performance of the bioactive 
compound nanoparticle complex against selected human cell lines 
and microorganisms.
THE ERA OF NANOTECHNOLOGY IN PHARMACEUTICAL SCIENCES
Nanotechnology was introduced into pharmaceutical sciences in the 
19th century when Paul Ehrlich during his study described it a magic 
bullet, which was employed to specifically deliver the drug of interest to 
the target cell without much effect to the host system. This necessitated 
further studies into the transition of particle size from microscale to 
nanoscale [52]. Drug targeting attracted interest in the recent years due 
to the fact that drugs possess both positive and negative effects on the 
host cells. The requirement/properties of ideal drug delivery system 
include being able to be extended into the blood circulation and must 
be targeted against a selected disease targets. Furthermore, it must be 
able to accurately deliver the drug of interest and has also been able 
to be excreted from the body through normal metabolic pathways. 
Hence, many materials have presently been studied for application 
as drug delivery systems with different manufacturing methods and 
modifications being established, while others are investigated for 
potential activities against target cells [52].
During the early days of nanoparticles development, they were 
initially used as carriers for the delivery of vaccines and anticancer 
drugs for improved uptake. Furthermore, studies were carried out 
on ways to reduce the intake of the nanoparticles by the cells of the 
reticuloendothelial system [53]. Nanoparticles for pharmaceutical use 
have to do with evolving technologies as a way of addressing emerging 
diseases and improvement of the drug delivery systems. Drug delivery 
systems ought to have an impact on the rate of absorption, metabolism, 
distribution, as well as excretion of the drug metabolites in a positive 
way. Similarly, drug delivery systems ought to permit the drugs to 
actively bind to their target cells and enhance receptor’s signaling and 
response [53].
Nanoparticles as drug delivery agents
Peptides and proteins delivery
The increase in the number of biotechnological molecules such 
as monoclonal antibodies, vaccines, and hormone, as well as their 
pharmaceutical potentials, makes it interesting for studies into the 
protein delivery system [54]. In the structure of proteins, stability is 
mainly a result of the balance between stabilizing and destabilizing 
forces exerting effects on the secondary, tertiary, and quaternary 
structures of the protein. The formation and maintenance of the stability 
of these structures are based on weak interactions such as electrostatic 
interactions, van der Waals force, and hydrogen bonding which hold 
these structures together. Alteration of any of these weak forces shifts 
the delicate balance of these protein structures and destabilizes the 
proteins [54]. The physical and chemical stability of these proteins 
can be altered by external factors such as pH, temperature, pH, ionic 
strength, high pressure, metal ions, non-aqueous solvents, adsorption, 
detergents, and agitation.
Solid lipid particulate systems such as solid lipid nanoparticles (LNs), 
lipospheres, and lipid microparticles have been used as an alternative 
delivery system for therapeutic peptides, antigens, and proteins, and 
research in this regard confirms that under optimized conditions, 
these particulate systems could be produced to incorporate hydrophilic 
or hydrophobic proteins and could serve as a particulate carrier 
system. Proteins and antigens meant for pharmaceutical purposes 
may be encapsulated or adsorbed onto the particulate system and 
administered by various routes such as through parenteral, oral, 
Table 3: Antibacterial activity of the methanolic extracts and standard drugs (mean±SD)
Bacteria Coprinus comatus (cultivated)  
(mg/mL)
Coprinus comatus (wild)  
(mg/mL)
Ampicillin (mg/mL) Streptomycin (mg/mL)
Staphylococcus aureus
MIC 0.0625±0.00 1.5±0.10 0.25±0.05 0.04±0.00
MBC 0.125±0.00 3.0±0.30 0.37±0.02 0.09±0.00
Bacillus cereus
MIC 0.0625±0.00 0.75±0.00 0.25±0.00 0.09±0.00
MBC 0.125±0.01 3.0±0.10 0.37±0.02 0.17±0.01
Myotis flavus
MIC 1.5±0.10 1.5±0.30 0.25±0.03 0.17±0.02
MBC 3.0±0.30 6.25±0.30 0.37±0.00 0.34±0.02
Listeria monocytogenes
MIC 0.75±0.10 3.0±0.10 0.37±0.01 0.17±0.01
MBC 3.0±0.00 6.25±0.30 0.49±0.03 0.34±0.00
Pseudomonas aeruginosa
MIC 0.35±0.03 1.5±0.30 0.74±0.02 0.17±0.04
MBC 3.0±0.10 3.0±0.30 1.24±0.00 0.34±0.03
Salmonella typhimurium
MIC 3.0±0.30 1.5±0.00 0.37±0.01 0.17±0.00
MBC 6.25±0.10 3.0±0.00 0.49±0.03 0.34±0.01
Escherichia coli
MIC 3.0±0.10 3.0±0.10 0.25±0.05 0.17±0.03
MBC 6.25±0.01 6.25±0.30 0.49±0.05 0.34±0.02
Enterobacter cloacae
MIC 3.0±0.10 1.5±0.10 0.37±0.05 0.26±0.01
MBC 6.25±0.10 6.25±0.00 0.74±0.07 0.52±0.02
Adapted from [45]. SD: Standard deviation, MIC: Minimum inhibitory concentration, MBC: Minimum bactericidal concentration
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nasal, or pulmonary routes. The encapsulation of the proteins in the 
particulate system adds to the stability of the protein, avoids proteolytic 
degradation, and also ensures a sustained release of the incorporated 
material [51]. In application, lipid particulate systems have been used 
as a delivery system of drugs where higher amounts of the drug were 
found in the brain after intravenous injection, suggesting the potential 
use of the particulate system in delivering drugs to the brain without 
crossing the blood–brain barrier [55].
Antitumor drugs delivery
Some of the characteristics which prompted the use of nanoparticles 
for the delivery of antitumor drugs include the following: (a) delivery of 
reasonable amount of drug within the surrounding of the target tumor 
through the enhanced retention and permeability or ligands active 
targeting on the surface of the nanoparticles and (b) reduction of the 
exposure of healthy cells and tissues to the drugs through the limitation 
of drug distribution to only target tissues and organs. Researchers 
have demonstrated that the hydrophobicity, biodegradation profile, 
drugs molecular weight, localization in the nanosphere, mode of 
incorporation and absorption have an influence on how drugs 
attached to nanoparticles are distributed inside the body. Although the 
major mechanism is yet to be fully understood, the biodistribution of 
nanoparticles is fast and could be completed within 60-180 minutes, 
prompting that the activity of the mononuclear phagocytic system 
(MPS) and the endocytosis/phagocytosis process might be involved. 
Such propensity of nanoparticles biodistribution gives the opportunity 
to efficiently deliver drugs to the target cells without adverse effect 
to the surrounding healthy cells and tissues. The effectiveness of 
the biodistribution of drugs through the nanopathway could be of 
importance in the chemotherapeutic treatment of organs laden with 
MPS-localized tumors such as hepatocarcinoma and hepatic metastasis 
hepatic metastasis originating from digestive tract, bronchopulmonary 
tumors, gynecological cancers, primitive tumors and metastasis, 
myeloma, small cell tumors, and leukemia [56,57].
Dermatology drug delivery
In the field of nanotechnology, manufacturing of elaborate nanosized 
particles for several applications has been allowed in recent times. 
Some of the new applications of this technology include the controlled 
release of drugs to skin and its appendages, transcutaneous vaccination, 
hair follicle (HF) targeting, and transdermal gene therapy. The delivery 
systems of this new generation carrier take the advantages of an 
enhanced skin penetration potentials, surface functionalization, and 
depot effect with sustained drug release, thereby allowing targeting 
of specific cells. The treatment of various types of skin diseases could 
be revolutionized through the use of nanomaterials as the delivery 
systems [57].
Of particular interest in the field of dermal drug delivery through the 
nanopathway is delivery with LN. This has been demonstrated to be 
effective for the treatment of the diseases of the HF, for an increased 
local bioavailability of active pharmaceutical ingredient (API) at their 
drug target. Nelson et al. identified that isotretinoin can cause the arrest 
of a cell cycle as well as apoptosis in sebocytes [58], whereas Messenger 
and Rundegren reported that minoxidil activated the synthesis of the 
vascular endothelial growth factor and prostaglandin in the dermal 
papilla [59], cyclosporine A was also reported by Takahashi and 
Kamimura to support the growth of hair epithelial cell growth [60]. 
In dermal therapy, the major objective is to reduce the systemic side 
effects of drugs through local administration of the API. The idea of 
using nanotechnology for the delivery of these drugs is already making 
gains and further development guarantees effective drug delivery to 
target cells without adverse effects on the surrounding healthy cells.
In cosmetics
Studies have shown promising areas of nanoparticles been used 
in several cosmetic products such as deodorant, toothpaste, soaps, 
shampoo, anti-wrinkles, hair conditioners, moisturizing creams, 
foundation, lipsticks, face powder, eye shadows, nail polishes, and 
perfumes. Nanoparticles (nanostructured lipid carriers) have been 
shown as a potential next-generation cosmetic delivery agent capable of 
providing improved skin hydration, stability of the agent, bioavailability, 
and controlled occlusion [61].
Other applications of nanotechnology in cosmetics are as follows:
a. Sunscreens
 Gibson et al. studied advances in diffuse optical imaging with 
emphasis on ultraviolet (UV) filters and concluded that filters 
such as titanium dioxide (TiO2) and zinc oxide can be used in 
the nanoscale instead of higher forms to make sunscreens more 
transparent instead of being white [62].
b. Breast cream
 In the formulation of its breast cream using herbal products, 
St Herb Nano Breast Cream claims to have used a combination 
of nanomaterial and Pueraria mirifica, a Thai herbal plant during 
the production of the cream [63].
c. Hair care
 In hair care, the RBC Life Sciences Nanoceuticals have used 
nanoclusters in the formulation of its citrus mint shampoo and 
conditioners, which confer hair with a healthy shining look 
[64,65].
d. Make-up
 The use of nanodispersion technology has aided Serge Lutens 
Blusher to produce an extremely fine and light powder which 
possesses extraordinary properties with excellent elasticity, light 
diffusion, and extreme softness [65].
e. Moisturizers/anti-wrinkles
 The application of nanotechnology in cosmetics has helped in the 
manufacture of various moisturizing creams and anti-wrinkles. 
Lancôme encapsulated triceramide in its Hydra Zen Cream to 
renew the healthy look of the skin healthy, while L’Oreal Revitalift 
Double Lifting anti-wrinkle cream contains nanosomes of pro-
retinol A [65].
This is evidence of the application of nanotechnology not only in the 
treatment of diseases but also in the production of life-aiding products.
NANOPARTICLES WITH PHARMACOLOGICAL POTENTIALS
Various studies have been carried out on the pharmacopotential 
of various materials when used as nanoparticles. Most of the 
nanomaterials (sized >100 µm) when reduced to the nanoparticles 
(<100 µm) exhibited pharmacological properties which when tested 
against various cell lines and were able to inhibit or reduce the growth 
of major human cancer cell lines. The materials investigated showed 
antitumor, antioxidant, as well as antibacterial potentials. A mini review 
of some nanoparticles and their recent application for pharmacological 
benefits was carried out here with the intent of identifying the 
pharmacodynamics surrounding their application. This review 
should not be seen as an exhaustive review of all the nanomaterials 
of pharmacological potential because there are so many reviews and 
works covering various aspects of this topic.
Cerium oxide nanoparticles
Cerium oxide is an oxide of the rare earth metal cerium, which is a pale 
yellow to white powder with the chemical formula CeO2. Cerium oxide 
is an important product commercially and exists as an intermediate 
during the purification of the element from the ores. The cerium (IV) 
oxide is formed through the calcination of cerium oxalate or cerium 
hydroxide at a high temperature. The mechanism of action and 
biological properties of cerium oxide is well understood owing to the 
fact that its ions switch between two valence state (Ce3+ and Ce4+). This 
two-valence state exists on the surface of the cerium oxide when it is 
synthesized as a nanoparticle. This deficiency in charge resulting from 
Ce3+ is rightly compensated through the formation of oxygen vacancies, 
which confer to cerium nanoparticles (CNPs), an intrinsic antioxidant 
property [66-68].
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Mechanism of action
The mechanism of action of CNPs shares similarities with most 
naturally-occurring metalloenzymes, which utilizes the transition 
metals cofactors such as Fe, Cu, Zn, or Mn to scavenge ROS in cells. CNPs 
have been shown to mimic the enzyme superoxide dismutase (SOD), 
when the Ce3+ form of it reacts with superoxide, thereby changing to 
Ce4+ while simultaneously reducing the superoxide into hydrogen 
peroxide [27,69]. Similarly, the oxidation of Ce3+ to Ce4+ ions permits 
the scavenging of other reactive species such as hydroxyl radicals [70], 
NO [71], and peroxynitrite (ONOO) [68]. Consequently, Ce4+ can be 
reduced to Ce3+ during the oxidation of H2O2 to O2, just in the same 
manner as catalase enzyme [72]. Therefore, the synergistic pair of 
Ce3+ and Ce4+ can alternately and reversibly switch forth and back even 
while scavenging peroxides and superoxide [66,68,73].
When considering the catalase potentials and the SOD activities of 
CNPs together, it has been suggested that CNPs undergo a complete 
redox cycle during the scavenging of two superoxides and a hydrogen 
peroxide molecule [66], which will be a perfect way to limit/eliminate, 
in a sequential set of energy-free reactions, both superoxide and 
hydrogen peroxide [67], resulting in the freeing of the cells from the 
most abundant ROS. This ability of CNPs to self-regenerate antioxidants 
is a potential pharmacological tool, which will portray CNPs as a unique 
and attractive biological scavenger.
Recent application in pharmacological studies
During the study of the ability of cerium oxide nanoparticles to 
stimulate the proliferation of primary mouse embryonic fibroblasts 
in vitro, Popov et al. demonstrated that citrate-stabilized cerium oxide 
nanoparticles promoted the proliferative activity of primary mouse 
embryonic fibroblasts in vitro. They postulated that cerium oxide 
nanoparticles stimulated the proliferation of a cell in a wide range of 
concentrations, ranging from 10−3 М to10−9 M, through the reduction of 
intracellular levels of ROS at the lag phase of the cell growth. Finally, 
they concluded that nanocrystalline ceria could be considered as a 
basis for the effective and affordable source of supplements during cell 
culturing [74].
Furthermore, several studies have been conducted with regard to 
neuropathies, often associated with oxidative conditions. In this 
regard, CNP pharmacologic potentials were tested on several neuronal 
models, both with and without the introduction of external oxidative 
stress sources. Treatment with CNPs was found not to have affected 
the viability of neurons, rather there was an increment in the life span 
of the neuron of cells isolated from the spinal cord of the rat [75], as 
well as protecting the neurons from mechanically induced trauma [76]. 
Accordingly, the brain lesions caused by oxidative stress in the cases 
of stroke-induced hypoxia and cerebral ischemia were reduced by 
CNPs [77]. CNPs have also been tried for the treatment of Alzheimer’s 
disease, which is an oxidation related neurodegenerative disease, 
occasioned by the formation of beta-amyloid plaques [77]. Study on 
CNPs loaded with antibodies against beta-amyloids was tested in 
different cellular models, and the results show that the CNPs actually 
allowed the preservation of the normal neural cells morphology, while 
significantly inhibiting neuron agglomeration and apoptosis [78,79].
Platinum nanoparticles (PNPs)
The catalytic properties of the inert noble gasses such as palladium, 
gold, and platinum, when reduced to the nanoscale, are gaining 
mush research interest for potential application as pharmacological 
agents [80-82]. PNPs are considered promising materials for the 
treatment of conditions related to oxidative stress due to their potent 
antioxidant potential and experiments conducted by Hamasaki et al., 
and Kajita et al. have shown that PNPs can actually interact or react with 
various ROS such as superoxides and hydrogen peroxide in oxidative-
related diseases [83,84]. PNPs also possess SOD activity in a similar 
way as the CNPs which made them an interesting biological agent [85]. 
Irrespective of these interesting potentials and abilities of PNPs, Caputo 
et al. stated that the basic mechanism of action of the nanoplatinum and 
its catalase-like activity still remains to be either investigated or even 
postulated [86].
Recent application
Hamasaki et al. [83] investigated the use of PNPs in the scavenging 
of UV-induced ROS in HeLa cells and found that they were able to 
preserve the viability of the cells [83], while Onizawa et al. noted that 
the PNPs were able to shield experimental mice exposed to extracts 
from cigarette smoke extract, thereby reducing the development of 
neutrophilic inflammation in the lungs of the mice [87]. Furthermore, 
owing to their anti-inflammatory properties, the PNPs were found by 
Kim et al. to modulate the activation of the redox-sensitive NF-kappa B, 
as well as displaying interesting antiaging properties which are 
associated with its SOD and catalase-like activities and significantly 
extending the lifespan of Caenorhabditis elegans [88,89].
PNPs verses CNPs
Not long ago, Clark et al. compared the antioxidant properties of PNPs 
and cerium oxide nanoparticles, employing similar quantities of CNPs 
and PNPs with an average diameter of 16 and 1.9 nm, respectively. The 
study found that at an equal doses of 48 mg/mL, the CNPs were able to 
show higher in vitro SOD activity when compared to the PNPs which 
showed a lower SOD activity and also that the CNPs were more effective 
than platinum NPs in the protection of the human breast fibrosarcoma 
cells from cell death induced by the activities of hydrogen peroxide [90].
Zirconia nanoparticles
Research in the area of the behavior of acids has found that just the 
strength of an acid does not matter during selection but the type of 
acidity possessed (Brønsted or Lewis) which actually matters for an 
improved acidity and selectivity. Brown and Hargreaves in 1999 noted 
that the introduction of super acidity on acids improves its activity and 
increases its selectivity [91]. The successful inclusion of the sulfate 
group on the zirconia skeleton has improved its application which has 
projected sulfated zirconia as a potential particle of great importance 
in many reactions, which tends to be improved when the size of the 
sulfated zirconia is reduced to nanosize [92,93]. The antioxidant, 
antibacterial, and antitumor potentials of sulfated zirconia have been 
investigated and reported recently [8], which opened the way for more 
studies on the other applications of the sulfated zirconia in nanosize for 
pharmacological benefits.
Recent application
The cytotoxicity potential of sulfated zirconia nanoparticles was 
investigated recently by Mftah et al. on human breast cancer (MCF-7), 
human liver cancer (HepG2), human colon cancer (HT29), and normal 
human breast (MCF-10a) cells. The investigation using sulfated zirconia 
nanoparticles showed that the particles have significant cytotoxic 
effects against the HT29 cells at almost every tested concentration, 
while investigations with the MCF-7 and HepG-2 cells showed that at 
a concentration of 15.6 μg/mL, the particles had no significant adverse 
effect on the growth of the cells, while inhibiting the growth of all cell 
lines [8]. The study also reported that the IC50 values of sulfated zirconia 
nanoparticles against tested cell lines showed that the nanoparticles 
were more active against the HT-29 cells with an IC50 value of 
26.4 μg/mL, while the HepG-2 and MCF-7 cells showed IC50 values of 
61.8 and 81.8 μg/mL, respectively. The normal cells MCF-10a cells 
which were also tested as controls showed the least sensitivity to the 
sulfated zirconia nanoparticles, having an IC50 value of 151.63 μg/mL, 
compared to the breast cancer MCF-7 cells which were more sensitive, 
with a reported IC50 value of 89.9 μg/mL [8]. This is evidence of the 
antitumor potential of sulfated zirconia nanoparticle, demonstrating 
high sensitivity against tumor cells while at the same time showing 
lesser side effects to the normal cells.
The antimicrobial potential of sulfated zirconia was also tested against 
a range of microorganisms which are responsible for various human 
diseases. It was reported by Mftah et al. that the sulfated zirconia 
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nanoparticles presented powerful antimicrobial activity against 
Gram-negative and Gram-positive bacteria tested. P. aeruginosa and 
methicillin-resistant S. aureus (MRSA) were reported as the most 
sensitive organisms, followed by Salmonella choleraesuis and B. subtilis. 
Against the fungal elements tested (C. albicans), antifungal activity was 
not detected, showing that the organisms were resistant to the activities 
of the particles [8]. Following the reported activity of sulfated zirconia 
nanoparticles against the selected microorganisms and tumor cells, 
it stands to reason that sulfated zirconia has a potential application 
in the field of pharmacological studies for further investigation, 
understanding, and utilization of its pharmacological attributed for 
human benefits.
THE INTERACTION BETWEEN NANOMATERIALS AND THE HUMAN 
IMMUNE SYSTEM (NANOTOXICOLOGY)
To defend the body against a host of invaders, the immune 
system employs various mechanisms such as complex detection, 
communication, and execution systems to protect and defend the 
organism from diseases. The two most recognized immune systems 
are the innate and the adaptive immune systems, both working in 
a specialized and functionalized pattern to ward off infection [34]. 
Evidence of a cross-link between the specialized cells of the two immune 
systems exists, such as the neutrophils which are innate cells but also 
involved in the workings of the adaptive immune system [35]. Farrera 
and Fadeel had proposed, during the study of the relationship between 
the immune system and engineered nanomaterials, that most, if not all, 
of the adverse effects of engineered nanomaterials are exerted through 
direct effects on the cells of the innate system. The cells implicated 
here were listed as the dendritic cells (DCs), the macrophages, the 
phagocytes, and the antigen-presenting cells [94]. A brief review of the 
interaction of nanomaterials with the two recognized human immune 
systems is carried out here for a better understanding of the interaction 
because it takes two to tango [94].
Nanomaterials interaction with the innate immune system
Phagocytosis is the major process through which the innate immune 
system recognizes process and responds to invading allergens. The 
understanding of the major processes involved in the interaction of 
phagocytosis with nanomaterials as well as the different population of 
cells which made up the cell populations and how they are activated is 
essential. Macrophages, when activated, can be divided into classically 
activated macrophages M1 or alternatively activated macrophages 
M2 [95]. M1 macrophages are more pro-inflammatory and leaned 
toward the killing of pathogens, while M2 macrophages are responsible 
for anti-inflammatory, tissue repair, and wound healing. The presence 
of Th1 cytokines has the ability to polarize macrophages toward the 
M1 phenotype, and the Th2 immune responses can induce macrophage 
polarization toward the M2 phenotype. Recently, studies by Jones et al. 
demonstrated that experimental mouse that is prone to Th1 immune 
response cleared introduced nanoparticles at a slower rate than rats 
prone to Th2 [96]. In the human sense of application, the study showed 
that the nature or status of the human immune system can determine 
how the body can clear nanoparticles when introduced into the 
body [94].
Nanoparticles have been reported to cause undesired effect, mainly 
caused by the impairment of phagocytic activities. The nanoparticle, 
SWCNTs, for instance, has been investigated by Witasp et al. 
and found to cause impairment in the ability of macrophages to 
engulf dead cell targets [97]. Similarly, ultrafine carbon particles 
have been shown to impede the ingestion microorganisms by the 
macrophages of human alveolar [98]. The exposure of macrophages 
to nanoparticles has been shown to cause an impaired ability of 
the activated macrophages to transition from M1- to M2-like state 
which was associated with a reduced phagocytic activity of the 
macrophages toward some bacteria. It was however concluded that 
the biological effects of nanoparticles may be indirectly manifested 
solely after challenging the normal cell function, such as clearance 
of bacteria [99].
Nanomaterials interaction with the adaptive immune system
A basic knowledge of the composition of the adaptive system and how 
it works will help in the understanding of how it interacts with foreign 
bodies for either recognition or elimination. The major function of the 
adaptive immune system is to proffer antibody-mediated immunity 
against foreign bodies. It is constituted primarily with the Bursa of 
Fabricius (B) cells and the thymus-derived (T) cells. These cells are 
further specialized with the B-cells being responsible for antibody-
mediated (humoral) immunity while the T-cells are more involved in 
the direct engagement (cell-mediated) with foreign bodies. The T-cells 
are further functionalized according to the nature of their role in body 
defense. The T-helper cells also called the CD4+ are involved in boosting 
antibodies production from the B-cells, while the T-helper cells are 
further classified into Th1, Th2, and Th17 depending on their cytokine 
profiles and role. Cytotoxic T-cells or CD8+ is involved in the direct 
killing of viral-infected and malignant cells, but the maintenance of the 
immune regulatory function is done by the regulatory T-cells (the “self” 
and “non-self” recognition process). The DCs form the link between the 
innate and the adaptive immune system, which are effective phagocytic 
cells that can as well possess the capacity to process and present an 
antigen for recognition [100].
The targeting of the DCs may have advantages and disadvantages 
as well. Rightful targeting of the DCs might be beneficial in the area 
of vaccination, whereas an undesired targeting of DCs might lead to 
toxicity, which might even include nanomaterial toxicity. Studies have 
shown that nanoparticles may alter the role of DCs and consequently 
affect B- and/or T-cells. For instance, multi-walled carbon nanotubes 
(MWCNTs) have been reported by Laverny et al. to alter the ability of 
the human monocytes to differentiate into DCs [101]. In addition, Tkach 
et al. demonstrated that the pulmonary exposure of mice to SWCNTs 
induced reduced proliferation of T-cells of the spleen although the 
direct effects the nanotubes had on the DCs [102].
The introduction of nanomaterials can either stimulate or suppress 
the function of the immune system as demonstrated by Mitchell et al., 
who found out through their investigation with animal models that 
the inhalation of MWCNTs caused a systemic suppression of the mice 
immune system, causing a decreased T-cell proliferation rate in the 
spleen, believed to be caused by a signal from the spleen, most likely the 
transforming growth factor-beta secreted by alveolar macrophages. As 
already mentioned, nanoparticles have been shown to influence T-cell 
proliferation, typically through an effect on antigen-presenting cells, 
leading to an enhanced T-cell stimulatory capacity [103-107].
To show the effect or tolerance of nanoparticles in human models, 
Schanen et al. demonstrated that when human was exposed to TiO2, it 
caused an elevated level of inflammatory cytokines, with an increased 
maturation of the DCs. In addition, the material (TiO2) when in nanosize 
effectively primed the activation and proliferation of the native CD4+ 
T-cells, which were more effective than the same material when 
applied in the micrometer size [108]. All foreign materials introduced 
into the body elicit a kind of immune reaction and the outcome of 
such reaction determines how beneficial or harmful the material 
could be. Nanoparticles with more benefits are currently considered 
for pharmacological benefits considering the potential gains which 
outweigh the hazards.
THE PROPOSED SYNERGISTIC COMBINATION
A beneficial synergistic antitumor and antibacterial activities 
against bacterial and tumor cells could be the possible outcome of a 
combination/encapsulation of bioactive extracts from mushrooms 
onto the nanoparticles. The encapsulation process could be done either 
during the synthesis of the nanoparticle through incorporation into 
the nanoparticle skeleton or after the synthesis through the addition 
of a carrier on the surface of the nanoparticle. This is the basis for 
this review to serve as an eye opener on the possibility of achieving a 
greater pharmacological activity through the encapsulation of bioactive 
compounds on nanoparticles for an enhanced activity.
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CONCLUSION
Nanomaterials possess both intrinsic and acquired identities, while the 
immune system is made up of the innate and adaptive systems, and it 
could be simply presumed that the interactions between nanomaterials 
and the immune system could be reciprocal in the sense that when the 
body is exposed to the nanomaterial, it may facilitate inflammation 
which involves the innate immune cells, which may also in some cases, 
digest the nanomaterials, leading to the reduction of its toxicity [109]. 
Encapsulation of the bioactive extracts from mushrooms onto the 
nanoparticle structure could proffer a synergistic pharmacological 
activity against targeted bacterial and tumor cells.
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